Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunobridging Study: Immunogenicity and Safety of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) Vaccine as Heterologue Booster in Adult Subjects in Indonesia

NCT05918939 is registered in ClinicalTrials.gov with Dr. Soetomo General Hospital as lead sponsor.

NCT NCT05918939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunobridging Study: Immunogenicity and Safety of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) Vaccine as Heterologue Booster in Adult Subjects in Indonesia
Lead sponsor
Dr. Soetomo General Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
September 5, 2022
Completion date
September 5, 2023
Enrollment
350 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pandemic, covid-19 vaccines